Skip to content
NovAccess Global Logo
XSNX 0.18 0.00 0.00%
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
Menu
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
NovAccess Global Logo
XSNX 0.18 0.00 0.00%
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
Menu
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact

Tag: orphandrug

NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1

Orphan Drug Application Filing

Revolutionary advances in the  understanding of how our bodies can fight cancer, and how to put that information to use in treating existing tumors. NovAccess Global’s team of experts is working to strengthen the capability of the human body’s defense against cancer.

Youtube Facebook Twitter Linkedin

Privacy Policy

Forward-Looking Statements

Contact Us

  • info@novaccessglobal.com
  • Corporate HQ
  • 8584 E. Washington Street #127 Chagrin Falls, Ohio 44023
  • Research & Development
  • 2265 E. Foothill Blvd, Pasadena, CA 91107

JOIN US

Stay up-to-date with our journey

Facebook Twitter Linkedin

Privacy Policy

Privacy Policy

Forward-Looking Statements